옵션 체인은 다양한 행사가격과 만기일에 대한 Northann의 주식 옵션 주요 데이터를 보여줍니다. 트레이더들은 이 정보를 사용하여 잠재적 거래를 분석하고 Northann에 대한 시장 심리를 평가합니다..

Northann (AMEX:NCL) 주식, 옵션 체인

Northann

Northann Corp specialized in 3D-printed flooring solutions under its flagship brand, "Benchwick." The company's operations span the full spectrum of additive manufacturing, from sourcing recycled ocean plastics to the final production of intricate flooring designs. Northann offers an extensive range of proprietary solutions, including Infinite Glass, DSE, TruBevel, and MattMaster, primarily through its sales network in North America and Europe.

Northann Corp

Norwegian Cruise Line Holdings Ltd. Ordinary Shares

Norwegian Cruise Line Holdings Ltd

Netcall PLC

NITORI HOLDINGS CO LTD by Nitori Holdings Co., Ltd.

Nitori Holdings Co Ltd

NITORI HOLDINGS CO U/ADR by Nitori Holdings Co., Ltd.

<p><strong>Numinus Wellness Inc.</strong> (OTCQX:<a class="ticker" href="https://www.benzinga.com/stock/NUMIF#OTCQX">NUMIF</a>), a leader in <a href="https://www.benzinga.com/topic/psychedelic-assisted-therapies">psychedelic-assisted mental health care</a>, has <a href="https://www.investors.numinus.com/news/news-details/2024/Numinus-Wellness-Announces-Sale-of-Clinics-and-Unique-Data-Partnership-to-Increase-Access-to-Mental-Health-Care/default.aspx">announced</a> a definitive agreement with <strong>Stella</strong>, an interventional psychiatry practice, to sell its five wellness clinics in Utah for a total of <strong>$3.53 million</strong>. The transaction, expected to close by November 30, marks a strategic shift for Numinus, as it pivots towards <a href="https://www.benzinga.com/markets/cannabis/24/09/40845569/mdma-therapy-for-ptsd-faces-fda-delay-are-there-other-ways-forward">developing technology-driven solutions</a> aimed at enhancing the efficiency of mental health care providers.</p>
<h3 class="wp-block-heading"><strong>Tech Partnership To Redefine Mental Health Clinics</strong></h3>
<p>In addition to the sale, Numinus and Stella will collaborate on a data-sharing initiative to launch an innovative clinic management platform. By leveraging operational insights from Stella's 12 clinics, Numinus plans to develop a software solution designed to streamline clinic operations, enhance patient outcomes and support insurance reimbursement processes.</p>
<p>"This transaction marks an exciting new chapter in Numinus' strategy to reshape behavioral health care," said <strong>Payton Nyquvest</strong>, founder and CEO of Numinus. "Leveraging our expertise in patient care, we're now accelerating our mission by focusing on cutting-edge technology solutions. Through our partnership with Stella, we gain unprecedented access to operational data that will enable us to develop a SaaS (software as a service) solution to redefine how clinics operate."</p>
<h3 class="wp-block-heading"><strong>Stella Takes Over Utah Operations</strong></h3>
<p>Stella, known for its focus on treating PTSD, anxiety and depression through biological modalities, will assume control of Numinus' Utah clinics. The acquisition includes an upfront payment of <strong>$2.08 million</strong>, followed by <strong>$750,000</strong> in installments throughout 2025, and up to <strong>$700,000</strong> in deferred compensation.</p>
<p>"Stella's expansion into Utah brings additional life-changing treatments to the community while supporting Numinus' broader tech initiatives," stated <strong>Michael Gershenzon</strong>, co-founder and CEO of Stella. "This partnership reflects our commitment to improving behavioral health systems and processes, ultimately enhancing patient care."</p>
<h3 class="wp-block-heading"><strong>An Asset-Light Business Model With Enhanced Focus</strong></h3>
<p>With the sale of its clinics, Numinus will shift towards an asset-light model, focusing on its business units like Cedar Clinical Research and the Numinus Network. The strategy aims to integrate clinical research, practitioner training and technology solutions, supporting mental health providers worldwide. The move is part of a broader effort to ease the operational burdens faced by healthcare professionals, particularly as demand for treatments like <a href="https://www.benzinga.com/topic/ketamine-therapy">ketamine</a> and Spravato continues to rise.</p>
<p>"Stella will bolster our clinical solutions offering, leveraging their deep expertise in patient care," Nyquvest added. "We expect strong demand for our Numinus Network Solutions as mental health practitioners navigate growing requests for care."</p>
<p><em>Cover image made with AI</em></p>


Cannabis

News

Psychedelics

NUMIF

Numinus Wellness Sells US Clinics, Partners With Stella For Tech-Driven Mental Health Solutions

<p>President-elect <strong>Donald Trump</strong> has chosen former Representative <strong>Doug Collins </strong>(R-GA) to lead the <a href="https://www.benzinga.com/cannabis">U.S. Department of Veterans Affairs (VA). </a></p>
<p>The decision has sparked discussions about how the agency might handle medical cannabis issues, given his inconsistent track record on the issue, as <a href="https://www.marijuanamoment.net/trumps-pick-to-lead-va-voted-against-letting-agency-doctors-recommend-medical-marijuana-to-veterans-before-he-adopted-a-pro-reform-position/">reported</a> Marijuana Moment.</p>
<h3 class="wp-block-heading"><strong>Collins' Record On Cannabis</strong></h3>
<p>During his time in Congress, Collins opposed efforts to expand access to medical cannabis for veterans. Between 2014 and 2016, he voted against three proposals that would have allowed VA doctors to recommend cannabis to their patients.</p>
<p><strong>See Also: <a href="https://www.benzinga.com/markets/cannabis/24/11/42018478/trumps-cabinet-choices-will-his-administration-support-or-restrict-cannabis">Trump&#8217;s Cabinet Choices: Will His Administration Support Or Restrict Cannabis?</a></strong></p>
<p>Collins' views began to shift in 2019. He supported the STATES Act, which would protect state marijuana programs from federal interference, and co-signed a letter with Rep. <strong>Matt Gaetz</strong> (R-FL), urging Congress to take action on cannabis policy. </p>
<p>"We believe this Committee and this Congress must act to clarify the rights and responsibilities, relative to cannabis, of individuals, physicians, businesses, medical patients, and law enforcement officials," they wrote.</p>
<p>Later that year, Collins backed a bipartisan bill to protect banks that serve marijuana businesses in states where it is legal. However, he did not take part in a 2020 vote on federal cannabis legalization.</p>
<h3 class="wp-block-heading"><strong>Collins' Stance On Psychedelics</strong></h3>
<p>When it comes to psychedelics, there isn't much known about Collins's stance. However, his shifting views on cannabis policy hint that he could be open to exploring different approaches.</p>
<h3 class="wp-block-heading"><strong>Cannabis At The VA</strong></h3>
<p>VA policy has long prohibited its doctors from recommending cannabis, citing marijuana's classification as a Schedule I controlled substance under federal law. This stance has remained consistent across both Republican and Democratic administrations, despite growing support for change in Congress.</p>
<p>Recent efforts to address this issue include a Senate Appropriations Committee request for the VA to explore cannabis as an alternative to opioids. Lawmakers have also introduced measures that would allow VA doctors to recommend cannabis in states where it is legal. These efforts have gained bipartisan support, but none have yet become law.</p>
<p>Veterans service organizations have pushed for further reforms, including expanded research into the potential benefits of cannabis. Last year, a Senate committee approved a bill to study cannabis for veterans with certain medical conditions, but it failed to advance to a floor vote.</p>
<p><strong>Read Next:</strong></p>
<ul>
<li><a href="https://www.benzinga.com/general/health-care/24/11/42017583/trumps-go-wild-on-health-plan-puts-rfk-jr-in-charge-what-it-means-for-cannabis-and-psychedelics-reform"><strong>Trump&#8217;s &#8216;Go Wild On Health&#8217; Plan Puts RFK Jr. In Charge: What It Means For Cannabis And Psychedelics Reform</strong></a></li>
</ul>
<p><em>Cover image made with AI.</em></p>


Government

Politics

Markets

Trump-Appointed Doug Collins To Lead VA: What's Next For Cannabis and Psychedelics In Veterans' Healthcare?

<p>Chardan Capital  analyst Daniil Gataulin   maintains Clearside Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLSD#NASDAQ">CLSD</a>) with a Buy and maintains $6 price target.</p>


Price Target

Analyst Ratings

CLSD

Chardan Capital Maintains Buy on Clearside Biomedical, Maintains $6 Price Target

<p>Chardan Capital  analyst Daniil Gataulin   maintains Cognition Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGTX#NASDAQ">CGTX</a>) with a Buy and maintains $11 price target.</p>


CGTX

Chardan Capital Maintains Buy on Cognition Therapeutics, Maintains $11 Price Target

<p>Telsey Advisory Group  analyst Cristina Fernandez   maintains Williams-Sonoma (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WSM#NYSE">WSM</a>) with a Outperform and maintains $165 price target.</p>


Telsey Advisory Group Maintains Outperform on Williams-Sonoma, Maintains $165 Price Target

<p><i>– Approval based on positive data from the AUGMENT-101 clinical trial, in which Revuforj delivered robust and durable rates of remission in R/R acute leukemia patients with a KMT2A translocation –</i></p>
<p><i>– Syndax to host conference call today at 6:00 p.m. ET –</i></p>
<p>WALTHAM, Mass., Nov. 15, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNDX#NASDAQ">SNDX</a>) today announced that the U.S. Food and Drug Administration (FDA) has approved Revuforj&#xAE; (revumenib) as the first and only menin inhibitor for the treatment of relapsed or refractory (R/R) acute leukemia with a lysine methyltransferase 2A gene (KMT2A) translocation in adult and pediatric patients one year and older. The FDA previously granted Breakthrough Therapy and Fast Track designations as well as Priority Review for Revuforj. The New Drug Application (NDA) received approval through the FDA's Real Time Oncology Review (RTOR) program.</p>


Biotech

General

SNDX

Syndax Announces FDA Approval Of Revuforj, The First And Only Menin Inhibitor To Treat Adult And Pediatric Patients With Relapsed Or Refractory Acute Leukemia With A KMT2A Translocation

<p>IT Tech Packaging (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/ITP#AMEX">ITP</a>) reported quarterly losses of $(0.20) per share. This is unchanged from the same period last year.  The company reported $25.08 million in sales this quarter. This is a 59.03 percent increase over sales of $15.77 million the same period last year.</p>


Earnings

IT Tech Packaging Q3 EPS $(0.20), Same YoY, Sales $25.08M Up From $15.77M YoY

<p>RumbleOn, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RMBL#NASDAQ">RMBL</a>) (the "Company" or "RumbleOn") announced today that the close of business (4:00 p.m. Central Time) on November 25, 2024 has been fixed as the record date (the "Record Date") for its previously announced proposed $10.0 million registered equity rights offering (the "Rights Offering"), which was announced in a Form 8-K filed with the U.S. Securities and Exchange Commission ("SEC") on November 12, 2024.</p>


Offerings

RMBL

RumbleOn Announces That The Close Of Business On November 25, 2024 Has Been Fixed As The Record Date For Its Previously Announced Proposed $10M Registered Equity Rights Offering

<p>Telsey Advisory Group  analyst Dana Telsey   maintains European Wax Center (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EWCZ#NASDAQ">EWCZ</a>) with a Outperform and maintains $8 price target.</p>


EWCZ

Telsey Advisory Group Maintains Outperform on European Wax Center, Maintains $8 Price Target

<p><a href="https://www.spglobal.com/spdji/en/documents/indexnews/announcements/20241115-1475367/1475367_4rcm.pdf" title="https://www.spglobal.com/spdji/en/documents/indexnews/announcements/20241115-1475367/1475367_4rcm.pdf">https://www.spglobal.com/spdji/en/documents/indexnews/announcements/20241115-1475367/1475367_4rcm.pdf</a></p>


FOUR

Shift4 Payments Will Replace R1 RCM In The S&P Midcap 400 Effective Prior To The Opening Of Trading On Wednesday, November 20

<p>China Green Agriculture, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CGA#NYSE">CGA</a>) has changed its name to Enlightify Inc., effective November 25, 2024. Its ticker symbol will change to ENFY effective November 25, 2024, and it is expected to begin trading under that symbol on November 26, 2024. The Company mainly produces and distributes humic acid-based compound fertilizers, other varieties of compound fertilizers and agricultural products through its subsidiaries in China.</p>


China Green Agriculture Changes Name to Enlightify Inc.; Its Ticker Symbol Will Change To 'ENFY' Effective November 25, 2024, And It Is Expected To Begin Trading Under That Symbol On November 26, 2024

<p>Alpha Cognition (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACOG#NASDAQ">ACOG</a>) reported quarterly losses of $(0.31) per share. This is a 63.1 percent increase over losses of $(0.84) per share from the same period last year.</p>


ACOG

Alpha Cognition Q2 EPS $(0.31) Up From $(0.84) YoY

<p>D. Boral Capital  analyst Jason Kolbert   maintains NRX Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NRXP#NASDAQ">NRXP</a>) with a Buy and maintains $31 price target.</p>


NRXP

D. Boral Capital Maintains Buy on NRX Pharmaceuticals, Maintains $31 Price Target

<p>D. Boral Capital  analyst Jason Kolbert   maintains VolitionRX (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/VNRX#AMEX">VNRX</a>) with a Buy and maintains $5 price target.</p>


VNRX

D. Boral Capital Maintains Buy on VolitionRX, Maintains $5 Price Target

<p>Luna Innovations Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUNA#NASDAQ">LUNA</a>) (the "Company"), a global leader in advanced fiber optic-based technology, today announced that it has received a written notice (the "Notice") on November 14, 2024, from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") stating that because the Company has not yet filed its Form 10-Q for the quarter ended September 30, 2024 (the "Q3 2024 Form 10-Q") and because the Company remains delinquent in filing its Form 10-Qs for the quarters ended March 31, 2024 (the "Q1 2024 Form 10-Q") and June 30, 2024 (the "Q2 2024 Form 10-Q") and its Form 10-K for the year ended December 31, 2023 (the "2023 Form 10-K", and collectively with the Q1 2024 10-Q, Q2 2024 10-Q and Q3 2024 10-Q, the "Delinquent Filings"), it is not in compliance with Nasdaq Listing Rule 5250(c)(1) (the "Rule"), which requires listed companies to timely file all required periodic financial reports with the Securities and Exchange Commission (the "SEC"). As previously announced, the Company received earlier notices of non-compliance with respect to the Rule on August 20, 2024, May 17, 2024 and April 2, 2024 because it had not yet filed its Q2 2024 Form 10-Q, Q1 2024 Form 10-Q and 2023 Form 10-K, respectively.</p>
<p>This Notice has no immediate effect on the listing of the Company's shares on Nasdaq. However, if the Company fails to timely regain compliance with the Rule, the Company's common stock will be subject to delisting from Nasdaq.</p>
<p>As previously disclosed on October 7, 2024, the Company intended to appeal a determination by the Nasdaq Listing Qualifications Department to delist the Company's securities due to the Company's Delinquent Filings. On October 8, 2024, the Company timely requested a hearing before the Nasdaq Hearings Panel (the "Panel") and requested that the automatic stay of suspension be extended through the completion of the hearings process and the expiration of any additional extension period granted by the Panel following the hearing. The hearing is scheduled for November 26, 2024 and the request for the automatic stay of suspension was granted.</p>
<p>The Company is working diligently to complete its Delinquent Filings and will provide an update once more information is available.</p>


LUNA

Luna Innovations Receives Additional Notice From Nasdaq Regarding Late Filing Of Quarterly Report On Form 10-Q; Hearing Is Scheduled For November 26, 2024 And The Request For The Automatic Stay Of Suspension Was Granted

<p>Barrington Research  analyst Kevin Steinke   maintains HireQuest (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQI#NASDAQ">HQI</a>) with a Outperform and raises the price target from $17 to $18.</p>


Barrington Research Maintains Outperform on HireQuest, Raises Price Target to $18

<p>Barrington Research  analyst Vincent Colicchio   maintains Alithya Group (TSX:<a class="ticker" href="https://www.benzinga.com/stock/ALYA#TSX">ALYA</a>) with a Outperform and maintains C$3.5 price target.</p>


TSX:ALYA

Barrington Research Maintains Outperform on Alithya Group, Maintains C$3.5 Price Target

<p>Lifeway Foods, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LWAY#NASDAQ">LWAY</a>) ("Lifeway" or the "Company"), a leading U.S. supplier of kefir and fermented probiotic products to support the microbiome, confirmed that it has received a revised, unsolicited, non-binding proposal from Danone North America PBC ("Danone") to acquire all outstanding shares of common stock of Lifeway it does not already own for $27.00 per share in cash. According to the Schedule 13D amendment filed today with the U.S. Securities and Exchange Commission disclosing the revised proposal, Danone beneficially owns approximately 23.3% of Lifeway's outstanding common stock.</p>
<p>On November 5, 2024, Lifeway announced that its Board of Directors (the "Board") had rejected Danone's initial unsolicited, non-binding proposal to acquire all the shares of Lifeway that it does not already own for $25.00 per share because the Board determined that the initial proposal substantially undervalued Lifeway and was not in the best interests of the Company and its shareholders and other stakeholders.</p>
<p>Consistent with its fiduciary duties, Lifeway's board of directors, in consultation with its independent outside advisors, will carefully review and evaluate the revised proposal to determine the course of action that it believes is in the best interests of the Company and its shareholders and other stakeholders.</p>
<p>The Company does not undertake any obligation to provide any updates with respect to this or any other proposal or transaction, except as required under applicable law.</p>
<p>Lifeway shareholders do not need to take any action at this time.</p>
<p>Evercore is serving as a financial advisor to Lifeway and Sidley Austin LLP is serving as legal counsel to Lifeway.</p>


LWAY

Lifeway Foods Confirms Receipt Of Revised, Unsolicited, Non-Binding Proposal From Danone  To Acquire All Outstanding Shares Of Common Stock Of Lifeway It Does Not Already Own For $27.00 Per Share In Cash

<p>Generation Income (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GIPR#NASDAQ">GIPR</a>) reported quarterly losses of $(0.03) per share. This is unchanged from the same period last year.  The company reported quarterly sales of $2.40 million which beat the analyst consensus estimate of $2.26 million by 6.21 percent.  This is a 30.17 percent increase over sales of $1.84 million the same period last year.</p>


Earnings Beats

GIPR

Generation Income Q3 FFO $(0.03), Same YoY, Sales $2.40M Beat $2.26M Estimate

<p>Shareholders Approve Waiver Of 19.99% Limit To Enable Additional Stock Issuance</p>


Stock Split

LUXH

LuxUrban Hotels Announces 1-For-70 Reverse Stock Split Effective Nov. 20 To Strengthen Nasdaq Compliance

Northann enters into partnership with Adornus Cabinetry

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p><strong>Northann</strong> (NYSEMKT:<span><a href="https://investorplace.com/stock-quotes/ncl-stock-quote/"><strong>NCL</strong></a></span>) just reported results for the first quarter of 2024.</p><ul><li>Northann reported earnings per share of 0.3 cent.</li><li>The company reported revenue of $4.60 million.</li></ul><div><p>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	<p>The post <a href="https://investorplace.com/earning-results/2024/05/ncl-stock-earnings-northann-for-q1-of-2024/">NCL Stock Earnings: Northann Reported Results for Q1 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

NCL Stock Earnings: Northann Reported Results for Q1 2024

Northann reports Q1 results

Northann Corp. (NCL) has provided an update. Northann Corp. recently finalized agreements with investors Sam Yan and Hongyu Wang to settle their se...

Northann Corp. Halves Debt with Savvy Investor Settlements

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p>The financial media does its best to keep you informed about what&rsquo;s happening in the market. However, this has the effect of giving significant attention to a handful of leaders or laggards. That creates an opportunity for investors who have the patience to look for must-own overlooked stocks. &nbsp;</p>



<p>Overlooked stocks are not necessarily underperforming the market. In some cases, these stocks simply are slow and steady at a time when investors want to find the newest and brightest shiny object. &nbsp;</p>



<p>However, not every shiny object is <strong>Nvidia</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/nvda-stock-quote/"><strong>NVDA</strong></a></span>). And the more light that starts shining on a high-profile stock, the more likely it is that the stock could move sharply lower on the slightest bit of bad news. &nbsp;</p>



<p>Another common misconception about overlooked stocks is that they come with a cheap price tag. This is also not necessarily true. In fact, sometimes a stock gets overlooked because it seems too expensive for retail investors. &nbsp;</p>



<p>In the end, must-buy overlooked stocks come down to value more than price. Because value always wins out over time. Here are seven stocks that investors are overlooking now but may shift back towards when market conditions change. &nbsp;</p>



<h2>AbbVie (ABBV)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2023/01/abbv1600-300x169.png" alt="Closeup of AbbVie (ABBV) building corporate office, an American biopharmaceutical company with its headquarters in Lake Bluff, Illinois, USA"><div>Source: Valeriya Zankovych / Shutterstock.com</div></div><p><strong>AbbVie</strong> (NYSE:<span><a href="https://investorplace.com/stock-quotes/abbv-stock-quote/"><strong>ABBV</strong></a></span>) is up 13.4% in the last 12 months but is down 11% in the last three months. The biopharmaceutical giant is being overlooked for a couple of reasons. First, with a price-to-earnings (P/E) ratio of around 40x, it&rsquo;s hardly a cheap stock. Second, investors want to see how the company&rsquo;s revenue and earnings will hold up now that its flagship Humira drug faces biosimilar competition in the U.S. and Europe.&nbsp;</p>



<p>When looking at the P/E ratio it&rsquo;s helpful to note that AbbVie has a forward P/E of around 13x earnings. That&rsquo;s much more attractive. &nbsp;</p>



<p>Then there&rsquo;s the Humira question. There&rsquo;s no doubt that the company is seeing pressure from competitors. In its April earnings report, AbbVie reported a <a href="https://investors.abbvie.com/static-files/af510304-0bc1-4781-9090-b6c4a9be5edb" target="_blank">39% decline in Humira revenue</a> in the United States. &nbsp;</p>



<p>However, AbbVie also <a href="https://investorplace.com/2024/05/7-safe-haven-stocks-to-weather-any-storm/" target="_blank">reported strong growth from two of its newer drugs</a>: Skyrizi and Rinvoq. These drugs are integral to the company&rsquo;s plans for replacing the lost Humira revenue. AbbVie also has a deep pipeline with <a href="https://www.abbvie.com/science/pipeline.html" target="_blank">50 drugs in mid- and late-stage development</a>. &nbsp;</p>



<p>Since the company&rsquo;s earnings report, analysts have assigned a <a href="https://www.tradingview.com/chart/aMepJfAr/?symbol=NYSE%3AABBV&amp;utm_source=www.marketbeat.com&amp;utm_medium=widget&amp;utm_campaign=chart-logo&amp;utm_term=NYSE%3AABBV" target="_blank">consensus price target of $182.90</a>. That&rsquo;s a 17% gain. Plus, AbbVie is a dividend king that not only has increased its dividend for 52 consecutive years, but the stock has an attractive yield of 3.98%. &nbsp;</p>



<h2>Johnson &amp; Johnson (JNJ)&nbsp;</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/10/jnj1600b-300x169.jpg" alt="jnj healthcare stocks"><div>Source: Raihana Asral / Shutterstock.com</div></div><p><strong>Johnson &amp; Johnson </strong>(NYSE:<span><a href="https://investorplace.com/stock-quotes/jnj-stock-quote/"><strong>JNJ</strong></a></span>) is another biopharmaceutical company on this list of must-own overlooked stocks. Unlike AbbVie, investors can&rsquo;t say that JNJ stock is expensive. It has a current P/E of 9x and a forward P/E of 13x. &nbsp;</p>



<p>Nevertheless, valuation remains an issue as investors are trying to price JNJ stock without its consumer products division that it spun off as <strong>Kenvue</strong> (NYSE:<span><a href="https://investorplace.com/stock-quotes/kvue-stock-quote/"><strong>KVUE</strong></a></span>) in 2023. The company is also working to resolve its long-running lawsuits stemming from its talc powder. In January, AbbVie announced it was moving forward on a <a href="https://www.cnn.com/2024/05/01/business/j-and-j-talc-cancer-lawsuits-settlement/index.html" target="_blank">$6.475 billion proposed settlement</a> of tens of thousands of lawsuits. However, there <a href="https://www.foxbusiness.com/markets/johnson-johnson-sued-cancer-victims-fraudulent-bankruptcies" target="_blank">may still be some work to do</a>. &nbsp;</p>



<p>The past shouldn&rsquo;t be overlooked. But the bullish case for JNJ stock is about the future. And its acquisition of<strong> Shockwave Medical</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/swav-stock-quote/"><strong>SWAV</strong></a></span>) is a key part of that. The <a href="https://investorplace.com/2024/04/wall-street-favorites-3-dividend-stocks-with-strong-buy-ratings-for-april-2024/" target="_blank">$13.1 billion acquisition</a> will bring Shockwave&rsquo;s first-to-market intravascular lithotripsy technology (ILT) under Johnson &amp; Johnson&rsquo;s MedTech division. &nbsp;</p>



<p>Once this acquisition becomes accretive to JNJ&rsquo;s top and bottom lines, JNJ stock will look extremely attractive for more than just its dividend which has a 3.48% yield. And with 62 years of consecutive dividend increases, Johnson &amp; Johnson is another dividend king on this list. &nbsp;</p>



<h2>PepsiCo (PEP)&nbsp;</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/02/pep-pepsico-1600-300x169.png" alt="Pepsi (PEP) Factory in Samara, Russia. Pepsi logo on a blue warehouse."><div>Source: FotograFFF / Shutterstock</div></div><p><strong>PepsiCo</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/pep-stock-quote/"><strong>PEP</strong></a></span>) is the third and final dividend king on this list of must-own overlooked stocks. The consumer staples giant has been largely able to <a href="https://investorplace.com/2024/05/7-reliable-blue-chip-stocks-that-cannot-miss/" target="_blank">pass along some of its higher producer costs</a>. But growth is slowing, and there is concern that consumer spending is slowing as well. Just as Pepsi benefits from both beverage and snack food sales when consumers trade up, it can suffer when consumers trade down. &nbsp;</p>



<p>This pessimism is reflected in PEP stock, which is essentially flat in 2024 and down about 5% in the last 12 months. That&rsquo;s not a massive dip to buy, but the stock is trading at around $170 which has served as a level of support and resistance in the last two years. &nbsp;</p>



<p>History shows that buying dips, no matter how small, in PEP stock is a solid strategy. One reason has to do with the company&rsquo;s previously mentioned dividend which yields 2.96% as of this writing and has been growing for 53 consecutive years. &nbsp;</p>



<h2>Sofi Technologies (SOFI)&nbsp;</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2023/10/sofi1600-1-300x169.png" alt="SoFi Technologies, Inc logo with stock market chart background. is an American online personal finance company and online bank."><div>Source: Poetra.RH / Shutterstock.com</div></div><p><strong>Sofi Technologies</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/sofi-stock-quote/"><strong>SOFI</strong></a></span>) falls under the category of &ldquo;yeah, but&rdquo; stocks. Okay, I invented the category, but the premise is this. Sofi has largely delivered what it has said it would do. It was an online lender primarily known for providing student loans. Yeah, but it wasn&rsquo;t a real bank. Then it got its&nbsp;bank charter. Yeah, but it wasn&rsquo;t profitable. Now it&rsquo;s delivered two straight quarters of positive adjusted EPS. &nbsp;</p>



<p>Still the stock can&rsquo;t seem to get out of the snares of short sellers. A considerable 18% of the SOFI stock float is being shorted. And with only 38% of the shares owned by institutions, it&rsquo;s been a tough hold. &nbsp;</p>



<p>SOFI stock is bouncing around $6.80. The good news is this has been a solid level of support. The bad news is that the company continues to revisit this level. The key will come from future growth, and in that regard being an internet-only bank <a href="https://investorplace.com/2024/05/secret-stocks-with-sizzle-3-low-profile-picks-packing-high-profit-potential/" target="_blank">lowers the company&rsquo;s customer acquisition costs</a>. &nbsp;</p>



<h2>Pfizer (PFE)&nbsp;</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/08/pfe-stock-2-300x169.jpg" alt="blue Pfizer logo on the windows of a corporate building PFR stock"><div>Source: photobyphm / Shutterstock.com</div></div><p><strong>Pfizer</strong> (NYSE:<span><a href="https://investorplace.com/stock-quotes/pfe-stock-quote/"><strong>PFE</strong></a></span>) is down 24% in the last 12 months and nearly 50% since its peak of near $60 in November 2021. The rise and fall of PFE stock was entirely predictable. The company was first-to-market with a vaccine for Covid-19. And it enjoyed the benefits of that position in its revenue and earnings. &nbsp;</p>



<p>However, as demand for the company&rsquo;s Covid-19 products wanes, so does the stock which is facing difficult comparisons. That said, Pfizer is being overlooked for many reasons, some of which have nothing to do with the intrinsic value of the stock. &nbsp;</p>



<p>That&rsquo;s part of the buying thesis. The mRNA technology that was used in the Covid-19 vaccine is already being used to develop other vaccines. The company is also making strides in oncology as well as areas such as <a href="https://www.pfizer.com/science" target="_blank">gene therapy and precision medicine</a>. And Pfizer has the balance sheet to get these products to the finish line whether it goes alone or through acquisition. &nbsp;</p>



<p>Analysts have a consensus Hold rating on PFE stock, but the price target is 37% higher. That&rsquo;s a discrepancy that makes it tempting to start a position. That&rsquo;s particularly true because, while you wait, you&rsquo;re getting a dividend with a 5.97% yield. &nbsp;</p>



<h2>Enphase Energy (ENPH)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2023/07/enph1600-300x169.png" alt="Smartphone with logo of American company company Enphase Energy Inc. (ENPH) on screen in front of business website. Focus on left of phone display. Unmodified photo."><div>Source: T. Schneider / Shutterstock.com</div></div><p><a href="https://investorplace.com/industries/energy/renewable-energy/solar/">Solar stocks</a> have been hit and miss for investors. There are stocks like <strong>First Solar</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/fslr-stock-quote/"><strong>FSLR</strong></a></span>) that are ripping higher. But a company like <strong>Enphase Energy </strong>(NYSE:<span><a href="https://investorplace.com/stock-quotes/enph-stock-quote/"><strong>ENPH</strong></a></span>), which was a darling of the solar sector in 2021 and 2022 has been having a rough time. &nbsp;</p>



<p>The company serves a largely residential audience and has been faced with declining revenue which has caused earnings to turn negative. Simply put, Enphase desperately needs a rate cut that will stimulate home buying and consumer investment in solar technology. &nbsp;</p>



<p>That may have to wait until 2025, but here&rsquo;s why you may want to put Enphase on a list of must-own overlooked stocks. Analysts have a consensus price target of $127.12. That&rsquo;s 2% lower than the price as of this writing. But <a href="https://www.tradingview.com/chart/aMepJfAr/?symbol=NASDAQ%3AENPH&amp;utm_source=www.marketbeat.com&amp;utm_medium=widget&amp;utm_campaign=chart-logo&amp;utm_term=NASDAQ%3AENPH" target="_blank">22 out of 42 analysts give ENPH stock a Strong Buy or Buy rating</a>. That suggests there may be a bigger dip coming for ENPH stock, but that would be a good time to take a position. &nbsp;</p>



<h2>Norwegian Cruise Line (NCLH)&nbsp;</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/06/nclh-1600-1-300x169.jpg" alt="Norwegian Cruise Line ship arriving at a port. NCLH stock."><div>Source: Ian_Stewart / Shutterstock</div></div><p>Cruise line stocks were a no-brainer long-term buy in 2020 and 2021. The industry was decimated by the global pandemic. But the smart money knew the industry would come back as it has. However, <strong>Norwegian Cruise Line</strong> (NYSE:<span><a href="https://investorplace.com/stock-quotes/nclh-stock-quote/"><strong>NCLH</strong></a></span>) has been largely ignored. Investors have a high bar and little patience. All it took was a slight miss on the top line to spook investors and turn NCLH stock negative for the year.&nbsp;</p>



<p>But this could be the stock&rsquo;s time to shine. Analysts are lining up behind Norwegian on expectations of earnings growth that could reach 30%, not just this year but for each of the next three years. That would help the cruise line retire a significant chunk of the $14 billion net debt load it&rsquo;s still carrying. &nbsp;</p>



<p>To deliver on those projections, it seems like the company is counting on younger travelers. The company recently cited millennial and Gen-Z passengers as being its <a href="https://www.nbclosangeles.com/news/business/money-report/norwegian-cruise-line-ceo-says-millennials-and-gen-z-are-the-fastest-growing-segment/3416765/" target="_blank">fastest growing demographic</a>. That could be a double-edged sword if the economy worsens. However, over time these are the passengers that will have growing income to spend on experiences. &nbsp;</p>



<p><em>On the date of publication, Chris Markoch did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the </em>InvestorPlace.com<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank"><em> </em>Publishing Guidelines.</a>&nbsp;</p>
<div><p>Chris Markoch is a freelance financial copywriter who has been covering the market for over five years. He has been writing for InvestorPlace since 2019.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	
<p>The post <a href="https://investorplace.com/2024/06/7-must-own-overlooked-stocks-that-can-work-in-any-portfolio/">7 Overlooked Stocks That Belong in Every Portfolio </a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

7 Overlooked Stocks That Belong in Every Portfolio

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p>We have all of the biggest pre-market stock movers that traders will want to read about on Monday morning!</p>



<p>Moving stocks this morning an investor update, clinical trial news, a private offering and more.</p>



<p>Let&rsquo;s get into that news below!</p>



<h2>Biggest Pre-Market Stock Movers: 10 Top Gainers</h2>



<ol><li><strong>Scinai Immunotherapeutics</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/scni-stock-quote/"><strong>SCNI</strong></a>) stock is rocketing more than 69% alongside heavy pre-market trading.</li>



<li><strong>Schmid Group</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/shmd-stock-quote/"><strong>SHMD</strong></a></span>) shares are soaring 40% without any clear news this morning.</li>



<li><strong>ENDRA Life Sciences</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/ndra-stock-quote/"><strong>NDRA</strong></a>) stock is surging over 36% alongside an <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318395592&amp;type=PDF&amp;symbol=NDRA&amp;cdn=4506ae3b1a739822361489bedc53ef84&amp;companyName=ENDRA+Life+Sciences+Inc.&amp;formType=SC+13G&amp;formDescription=Statement+of+acquisition+of+beneficial+ownership+by+individuals&amp;dateFiled=2024-06-14">investor stake update</a>.</li>



<li><strong>Maxeon Solar Technologies</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/maxn-stock-quote/"><strong>MAXN</strong></a>) shares are rising more than 21% with strong early morning trading.</li>



<li><strong>Srivaru </strong>(NASDAQ:<a href="https://investorplace.com/stock-quotes/svmh-stock-quote/"><strong>SVMH</strong></a>) stock is increasing over 18% as it continues to <a href="https://investorplace.com/2024/06/why-is-srivaru-svmh-stock-up-122-today/">rally on e-bike news</a>.</li>



<li><strong>Nurix Therapeutics</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/nrix-stock-quote/"><strong>NRIX</strong></a>) shares are gaining 17% on <a href="https://www.marketwatch.com/story/nurix-therapeutics-shares-rise-on-positive-leukemia-drug-results-66b9d524?mod=investing">positive drug results</a>.</li>



<li><strong>Icecure Medical</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/iccm-stock-quote/"><strong>ICCM</strong></a>) stock is getting a 14% boost with it still rallying on <a href="https://www.nasdaq.com/press-release/positive-data-icecures-kidney-cancer-clinical-study-presented-interventional">kidney cancer study data</a>.</li>



<li><strong>Kineta </strong>(NASDAQ:<a href="https://investorplace.com/stock-quotes/ka-stock-quote/"><strong>KA</strong></a>) shares are heading more than 13% higher with heavy trading today.</li>



<li><strong>XTL Biopharmaceuticals</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/xtlb-stock-quote/"><strong>XTLB</strong></a>) stock is jumping over 12% this morning.</li>



<li><strong>Conn&rsquo;s </strong>(NASDAQ:<a href="https://investorplace.com/stock-quotes/conn-stock-quote/"><strong>CONN</strong></a>) shares are up more than 11% today.</li>
</ol><h2>10 Top Losers</h2>



<ol><li><strong>Kaival Brands Innovations</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/kavl-stock-quote/"><strong>KAVL</strong></a>) stock is plummeting more than 35% after a massive rally on Friday.</li>



<li><strong>Sonim Technologies</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/sonm-stock-quote/"><strong>SONM</strong></a>) shares are diving over 25% this morning.</li>



<li><strong>AMC Networks</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/amcx-stock-quote/"><strong>AMCX</strong></a>) stock is tumbling more than 23% after <a href="https://www.nasdaq.com/press-release/amc-networks-inc-announces-private-offering-125-million-convertible-senior-notes-2024">announcing a private offering</a>.</li>



<li><strong>Bluejay Diagnostics</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/bjdx-stock-quote/"><strong>BJDX</strong></a>) shares are taking an over 17% beating despite a lack of news.</li>



<li><strong>Northann </strong>(NYSEMKT:<a href="https://investorplace.com/stock-quotes/ncl-stock-quote/"><strong>NCL</strong></a>) stock is falling close to 14% without any news to report.</li>



<li><strong>Zapp Electric Vehicles</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/zapp-stock-quote/"><strong>ZAPP</strong></a>) shares are dropping more than 13% as it <a href="https://investorplace.com/2024/06/why-is-zapp-electric-vehicles-zapp-stock-up-173-today/">comes off a rally last week</a>.</li>



<li><strong>Aptevo Therapeutics</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/apvo-stock-quote/"><strong>APVO</strong></a>) stock is decreasing over 13% on a <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318396271&amp;type=PDF&amp;symbol=APVO&amp;cdn=21e6c068c48621c307f0f74bc8553007&amp;companyName=Aptevo+Therapeutics+Inc.&amp;formType=S-1&amp;formDescription=Registration+statement+under+Securities+Act+of+1933&amp;dateFiled=2024-06-14">proposed public offering</a>.</li>



<li><strong>Feutune Light Acquisition</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/flfv-stock-quote/"><strong>FLFV</strong></a>) shares are slipping almost 12% on Monday.</li>



<li><strong>Volcon </strong>(NASDAQ:<a href="https://investorplace.com/stock-quotes/vlcn-stock-quote/"><strong>VLCN</strong></a>) stock is dipping more than 11% on <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318396398&amp;type=PDF&amp;symbol=VLCN&amp;cdn=980b1d9c3f018f25ac11de4d0e102b66&amp;companyName=Volcon+Inc.&amp;formType=8-K&amp;formDescription=Current+report+pursuant+to+Section+13+or+15%28d%29&amp;dateFiled=2024-06-14">a delisting notice</a>.</li>



<li><strong>Holdco Nuvo</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/nuvo-stock-quote/"><strong>NUVO</strong></a>) shares close out our pre-market stock movers down over 11% today.</li>
</ol><p><em>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;</em><a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank"><em>Publishing Guidelines</em></a><em>.</em></p>
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	<p>The post <a href="https://investorplace.com/2024/06/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-monday-june-17th/">Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday

Northann Corp. (NCL) has shared an update. Northann Corp. has announced its relocation to a new headquarters in South Carolina, having entered into...

Northann Corp.: Strategic Headquarters Relocation and Lease Deal

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p><strong>Northann</strong> (NYSEMKT:<span><a href="https://investorplace.com/stock-quotes/ncl-stock-quote/"><strong>NCL</strong></a></span>) just reported results for the second quarter of 2024.</p><ul><li>Northann reported earnings per share of -4 cents.</li><li>The company reported revenue of $3.89 million.</li></ul><div><p>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><p>The post <a href="https://investorplace.com/earning-results/2024/08/ncl-stock-earnings-northann-for-q2-of-2024/">NCL Stock Earnings: Northann Reported Results for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

NCL Stock Earnings: Northann Reported Results for Q2 2024

Jobs Report Sends Mixed Signals, But Another Rate Cut Is Still Very Likely

FOXO Technologies, Tivic Health Systems, and Northann Corp. are the 3&nbsp;Penny Stocks&nbsp;to watch on November 12, 2024, based on&nbsp;TipRanks'...

3 Penny Stocks to Watch Now, 11/12/24

ABBV

ACTV

AFMC

AFSM

AMCX

APVO

ARKK

AVUV

BAPR

BJDX

CONN

ENPH

FLFV

FOXO

FSLR

ICCM

IVOO

IVOV

KAVL

KVUE

MAGS

MAXN

NDRA

NRIX

NUVO

NVDA

SCNI

SHMD

SOFI

SONM

SPLV

SPMD

SPMO

SPMV

SPSM

SPUS

SPUU

SPVM

SPVU

SPXE

SPXL

SPXN

SPXS

SPXT

SPXU

SPXV

SPYD

SPYG

SPYV

SPYX

SQEW

SQLV

SSPY

SVAL

SVMH

SWAV

SYLD

TIVC

TMDV

TPHD

TPLC

TPSC

UAUG

UJAN

UMAR

UMAY

UOCT

UPRO

USMC

USMF

USVM

VLCN

XTLB

ZAPP

Press Releases

Northann Corp.'s Benchwick Brand to Showcase SuperOak Hybrid Wood Planks Alongside Blue11 Collection at NWFA in New Orleans, April 16-18, 2024

Expo Presentations and Cross-Licensing with I4F to Expand Business for 3D-Printed Ecosystem Flooring and Wall Panel Products Made with Recycled Ocean Plastics: Northann Corp (NYSE: NCL)

Northann Corp Enters Strategic Relationship with Rexil Group of Companies Netherlands to Promote Sustainable Technology and Products

Strategic Relationships Cross-Licensing and Sourcing are Globally Expanding 3D-Printed Ecosystem Flooring and Wall Panel Products Made with Recycled Ocean Plastics: Northann Corp. (NYSE: NCL)

Northann Corp.'s Blue11-Ocean Plastic Flooring and Wall Panels Product Wins Multiple Prestigious Awards in 2024

6 Prestigious Awards and Expanding Global Marketing and Licensing for Eco-Friendly 3D-Printed Flooring & Wall Panel Products Made Using Recycled Ocean Plastics: Northann Corp. (NYSE: NCL)

Northann Corp. Announces Strategic Partnership with Adornus Cabinetry

Relationships with Adornus Cabinetry, Rexil Group and I4F; Multiple Awards for 3D-Printed Flooring & Wall Panel Products Made Using Recycled Ocean Plastics: Northann Corp. (NYSE: NCL)

Comments

Northann

Northann (NCL) 옵션

No option chain data available. Please try again later

뉴스

파트너 / 기고자

벤징가 글로벌